Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, L. A.
Right arrow Articles by Ruckdeschel, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, L. A.
Right arrow Articles by Ruckdeschel, J. C.
(Chest. 2003;123:202S-220S.)
© 2003 American College of Chest Physicians

Treatment of Stage IIIA Non-small Cell Lung Cancer*

Lary A. Robinson, MD, FCCP; Henry Wagner, Jr., MD and John C. Ruckdeschel, MD, FCCP

* From the Thoracic Oncology Program, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL.

Correspondence to: Lary A. Robinson, MD, FCCP, Division of Cardiovascular and Thoracic Surgery, Thoracic Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: robinson{at}moffitt.usf.edu

Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky multistation nodal disease. Controversy abounds as to the optimal treatment of the various stage IIIA subsets, which is fueled by a lack of meaningful, large randomized trials. Multimodality therapy of some type appears to be preferable in stage IIIA patients.

Key Words: adjuvant chemotherapy • adjuvant radiotherapy • chemotherapy • guidelines • lung carcinoma • neoadjuvant therapy • non-small cell lung cancer • pulmonary surgical procedures • radiation therapy




This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
L. W. Martin, A. M. Correa, W. Hofstetter, W. K. Hong, R. Komaki, J. B. Putnam Jr, D. C. Rice, W. R. Smythe, S. G. Swisher, A. A. Vaporciyan, et al.
The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1601 - 1610.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.